| Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences S Aringhieri, M Carli, S Kolachalam, V Verdesca, E Cini, M Rossi, ... Pharmacology & therapeutics 192, 20-41, 2018 | 230 | 2018 |
| Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences M Carli, S Kolachalam, B Longoni, A Pintaudi, M Baldini, S Aringhieri, ... Pharmaceuticals 14 (3), 238, 2021 | 182 | 2021 |
| Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health B Lovrecic, M Lovrecic, B Gabrovec, M Carli, M Pacini, AGI Maremmani, ... International Journal of Environmental Research and Public Health 16 (2), 177, 2019 | 64 | 2019 |
| Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism S Aringhieri, S Kolachalam, C Gerace, M Carli, V Verdesca, MG Brunacci, ... European Neuropsychopharmacology 27 (4), 383-398, 2017 | 45 | 2017 |
| Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them? M Carli, S Kolachalam, S Aringhieri, M Rossi, L Giovannini, R Maggio, ... Current neuropharmacology 16 (2), 222-230, 2018 | 43 | 2018 |
| GPCRs in Intracellular Compartments: New Targets for Drug Discovery I Fasciani, M Carli, F Petragnano, F Colaianni, G Aloisi, R Maggio, ... Biomolecules 12 (10), 1343, 2022 | 37 | 2022 |
| Melatonin as a chronobiotic with sleep-promoting properties F Cruz-Sanabria, C Carmassi, S Bruno, A Bazzani, M Carli, M Scarselli, ... Current Neuropharmacology 21 (4), 951-987, 2023 | 34 | 2023 |
| Is adult hippocampal neurogenesis really relevant for the treatment of psychiatric disorders? M Carli, S Aringhieri, S Kolachalam, B Longoni, G Grenno, M Rossi, ... Current Neuropharmacology 19 (10), 1640-1660, 2021 | 33 | 2021 |
| Opioid receptors beyond pain control: The role in cancer pathology and the debated importance of their pharmacological modulation M Carli, S Donnini, C Pellegrini, E Coppi, G Bocci Pharmacological Research 159, 104938, 2020 | 31 | 2020 |
| Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics I Fasciani, F Petragnano, G Aloisi, F Marampon, M Carli, M Scarselli, ... Pharmaceuticals 13 (11), 388, 2020 | 30 | 2020 |
| Substance Use Disorder in Adult-Attention Deficit Hyperactive Disorder Patients: Patterns of Use and Related Clinical Features V Spera, A Pallucchini, M Maiello, M Carli, AGI Maremmani, G Perugi, ... International Journal of Environmental Research and Public Health 17 (10), 3509, 2020 | 27 | 2020 |
| Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Coexisting Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments F Weiss, S Tidona, M Carli, G Perugi, M Scarselli Current Neuropharmacology 21 (7), 1467-1476, 2023 | 13 | 2023 |
| Does Cannabis, Cocaine and Alcohol Use Impact Differently on Adult Attention Deficit/Hyperactivity Disorder Clinical Picture? V Spera, A Pallucchini, M Carli, M Maiello, AGI Maremmani, G Perugi, ... Journal of Clinical Medicine 10 (7), 1481, 2021 | 13 | 2021 |
| Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors? G Natale, E Fini, PF Calabrò, M Carli, M Scarselli, G Bocci Cancer Letters 560, 216125, 2023 | 12 | 2023 |
| A 5-Year Study of Lithium and Valproic Acid Drug Monitoring in Patients with Bipolar Disorders in an Italian Clinical Center M Carli, E Risaliti, M Francomano, S Kolachalam, B Longoni, G Bocci, ... Pharmaceuticals 15 (1), 105, 2022 | 12 | 2022 |
| Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo-and Heterodimers R Maggio, I Fasciani, M Carli, F Petragnano, F Marampon, M Rossi, ... Biomolecules 11 (12), 1828, 2021 | 11 | 2021 |
| Symptomatological Variants and Related Clinical Features in Adult Attention Deficit Hyperactive Disorder A Pallucchini, M Carli, M Scarselli, I Maremmani, G Perugi International Journal of Environmental Research and Public Health 18 (3), 922, 2021 | 10 | 2021 |
| Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes L Biso, S Aringhieri, M Carli, M Scarselli, B Longoni Pharmaceuticals 17 (5), 642, 2024 | 8 | 2024 |
| Pharmacological strategies for bipolar disorders in acute phases and chronic management with a special focus on lithium, valproic acid, and atypical antipsychotics M Carli, F Weiss, G Grenno, S Ponzini, S Kolachalam, F Vaglini, C Viaggi, ... Current Neuropharmacology 21 (4), 935-950, 2023 | 7 | 2023 |
| β-Cells Different Vulnerability to the Parkinsonian Neurotoxins Rotenone, 1-Methyl-4-phenylpyridinium (MPP+) and 6-Hydroxydopamine (6-OHDA) M Carli, F Vaglini, E Risaliti, G Citi, M Masini, S Kolachalam, R Maggio, ... Pharmaceuticals 14 (8), 767, 2021 | 7 | 2021 |